within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED04_Brigatinib;

model Brigatinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.92,
    Cl = 3.5277777777777775e-06,
    adminDuration = 600,
    adminMass = 180 / 1000000,
    adminCount = 1,
    Vd = 0.153,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.010333333333333333,
    Tlag = 9.66,
    Vdp = 0.0979,
    k12 = 6.944444444444445e-06,
    k21 = 6.944444444444445e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Brigatinib</td></tr><tr><td>ATC code:</td><td>L01ED04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>180</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>153</td><td>L</td></tr>
    <tr><td>clearance:</td><td>12.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Brigatinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). It is approved for use in patients whose disease has progressed on or who are intolerant to crizotinib.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in adult patients with advanced malignancies including ALK-positive NSCLC, mostly aged 18-84 years, under steady-state following repeated dosing.</p><h4>References</h4><ol><li><p>Gupta, N, et al., &amp; Venkatakrishnan, K (2021). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. <i>Clinical pharmacokinetics</i> 60(2) 235–247. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00929-4\">10.1007/s40262-020-00929-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32816246/\">https://pubmed.ncbi.nlm.nih.gov/32816246</a></p></li><li><p>Gupta, N, et al., &amp; Sinha, V (2023). Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. <i>Clinical pharmacokinetics</i> 62(8) 1063–1079. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01284-w\">10.1007/s40262-023-01284-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37493887/\">https://pubmed.ncbi.nlm.nih.gov/37493887</a></p></li><li><p>Tugnait, M, et al., &amp; Narasimhan, N (2019). The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 8(6) 734–741. DOI:<a href=\"https://doi.org/10.1002/cpdd.641\">10.1002/cpdd.641</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30570839/\">https://pubmed.ncbi.nlm.nih.gov/30570839</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01ED04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Brigatinib;
